Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationDavid R. Bangsberg, Andrew R. Moss, Mark Holodniy et al.|AIDS|2000Cited by 1k
Non-adherence to highly active antiretroviral therapy predicts progression to AIDSDavid R. Bangsberg, Andrew R. Moss, Sharon Perry et al.|AIDS|2001Cited by 964
HIV-1 Protease Mutations and Protease Inhibitor Cross-ResistanceSoo‐Yon Rhee, Robert W. Shafer, Jonathan Taylor et al.|Antimicrobial Agents and Chemotherapy|2010Cited by 230
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Jeffrey Enejosa et al.|The Journal of Infectious Diseases|2010Cited by 114